Vmbook Online ordering

Icons

ICON plc (ICLR) is a public company that is listed on the NASDAQ stock exchange in the USA. The company is based in Dublin, Ireland and is a global provider of clinical research services and technology solutions to the pharmaceutical, biotechnology, and medical device industries.

ICLR has a market capitalization of around $7 billion and reported revenue of $2.1 billion in 2020, representing a year-over-year growth of 4.5%. The company's earnings per share (EPS) for the same period were $3.41, representing a year-over-year growth of 11.4%.

ICLR operates in a highly competitive industry, but it has differentiated itself through its scale, therapeutic expertise, and innovative technology. The company's platform includes a range of services and solutions, from early-stage clinical development to post-marketing surveillance, and it has a strong presence in key therapeutic areas such as oncology, central nervous system disorders, and infectious diseases.

ICLR has also been investing heavily in research and development to drive growth. In 2020, the company invested $328 million in R&D, representing 16% of its revenue. This investment is expected to continue, as ICLR looks to expand its capabilities and continue to deliver innovative solutions to its clients.

In terms of stock performance, ICLR has had a strong run over the past year. The stock is up over 60% in the past 12 months, outpacing the broader market. The company's fundamentals remain strong, and it is well-positioned to continue delivering growth in the coming years.

Overall, ICLR is a strong company with a solid track record of growth and innovation. Its focus on clinical research and technology solutions, along with its strong presence in key therapeutic areas, make it a compelling investment opportunity in the healthcare sector.